These findings indicate that high-dose Vit-C and the anti-PD-L1 antibody can act synergistically to eliminate tumor cells, and that the immunotherapy effect of Vit-C-anti-PD-L1 combination is TET2-dependent. The gene discussed is TET2; the disease is neoplasm.